BioStock published an article on 3 June 2021 about Follicum, which can be read in full below. Many people’s hopes for Follicum’s hair loss project were dashed in May when the company presented top-line results demonstrating that the drug candidate FOL-005 did not show any significant effect compared to placebo. Hopes for the project were […]
BioStock published an article on 20 May 2021 about Follicum, which can be read in full below. Kim Arvid Nielsen recently took over as CEO of the research company Follicum, at a time when the company stands at an important junction for its further development work. BioStock has spoken to the newly appointed CEO to […]
BioStock published an article on 30 March 2021 about Follicum, which can be read in full below. Follicum, a company that develops tissue repair peptides, has advanced further in its preclinical work with developing a drug candidate for the treatment of diabetes. Through extensive and advanced experimental work, the company believes that the peptides bind […]
BioStock published an article on 1 February 2021 about Follicum, which can be read in full below. For Follicum, one of this year’s main events will be the topline result from the ongoing phase IIa study with the company’s candidate FOL-005 for treatment of hair loss. The company announced on Thursday that all patients in […]
BioStock published an article on 17 December 2020 about Follicum, which can be read in full below. A productive 2020 for Follicum is capped off by the completion of patient recruitment for its phase II hair growth study for determining the best dose and treatment duration of candidate FOL-005. BioStock spoke with Follicum’s CEO Jan […]
On 25 November 2020, Aktiespararna published their analysis of Follicum on their website. The analysis can also be read on Follicum’s webpage. Read the analysis at Aktiespararna.se For further information, please contact: Jan Alenfall – CEO, Follicum AB Telephone: +46 (0)709 31 51 15 Email: info@follicum.com About Follicum AB Follicum AB (Spotlight: FOLLI) develops drugs […]
BioStock published an article on 2 November 2020 about Follicum, which can be read in full below. Last week, biotech company Follicum announced a directed share issue of SEK 36.6 million to a number of selected investors. The funds will be used to bring the ongoing phase II trial in hair loss across the finish […]
BioStock published an article on 9 October 2020 about Follicum, which can be read in full below. Alopecia patients have very few treatment options available to them. Those that exist are often ineffective and come with a multitude of side effects, and they mainly target men. Follicum’s FOL-005 is a compound in clinical development that […]
BioStock published an article on 19 August 2020 about Follicum, which can be read in full below. Yesterday, Follicum announced that they have recruited over 50 per cent of the intended patient group for their ongoing phase IIa trial with the topical formulation of the hair growth stimulating candidate FOL-005. Thus, the study is well on […]
BioStock published an article on 25 June 2020 about Follicum, which can be read in full below. During the first half of 2020, Follicum has started, paused and resumed a phase II study with its primary candidate FOL-005. An international patent application has been filed regarding its newly developed topical formulation as a carrier of […]